Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection
Trial details
- Registry ID
- NCT02859961
- Drugs studied
- PRO 140 (350 mg), PRO 140 (525 mg), PRO 140 (700 mg)
TrialRedline tracks 10 clinical trials sponsored by CytoDyn, Inc.: 4 Phase 2 / 3, 6 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 InfectionNCT02859961 | PRO 140 (350 mg), PRO 140 (525 mg), PRO 140 (700 mg) | Completed | 2020-09-16Actual |
| PRO 140 in Treatment-Experienced HIV-1 SubjectsNCT03902522 | PRO 140 | Completed | 2020-05-18Actual |
| An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 StudyNCT05271370 | PRO 140 350, PRO 140 525, PRO 140 700 | Terminated | 2022-06-20Actual |
| An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label StudyNCT02990858 | PRO 140 | Terminated | 2022-06Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched RegimenNCT06699836 | 200 mg pembrolizumab, 350 mg leronlimab, 700 mg leronlimab | Active not recruiting | 2028-01Estimated |
| Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid TumorsNCT04504942 | Leronlimab | Completed | 2021-11-07Actual |
| Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19NCT04347239 | Leronlimab (700mg) | Completed | 2021-10-24Actual |
| Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19NCT04678830 | Leronlimab (700mg), Placebos | Completed | 2021-06-05Actual |
| An Extension of Protocol PRO 140_CD01 StudyNCT02355184 | PRO 140 350mg weekly subcutaneous (SC) injection. | Terminated | 2022-06Actual |
| A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell TransplantationNCT02737306 | PRO 140 | Terminated | 2021-04-14Actual |
Names as written in the registry records.
NCT06699836 · CytoDyn, Inc.
Before: Estimated. After: Actual.
Before: 60 participants (planned). After: 66 participants (actual).
Before: Recruiting. After: Active not recruiting.
NCT06699836 · CytoDyn, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To evaluate the efficacy of leronlimab in combination with trifluridine and tipiracil + bevacizumab in participants with CCR5+, refractory, MSS, mCRC.. After: Measure: The efficacy of leronlimab in combination with trifluridine and tipiracil + bevacizumab in participants with relapsed, refractory, MSS, mCRC..
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Proportion of participants who remain on PRO 140 monotherapy regimen at the end of week 48 without experiencing virologic failure. After: Measure: Proportion of Participants Who Remain on PRO 140 Monotherapy Regimen at the End of Week 48 Without Experiencing Virologic Failure.
Before: 556 participants (actual). After: 562 participants (actual).